Moreover, α-lipoic acid therapy or 1-week treatment with SSR240612, a selective B1R antagonist, reduced hyperglycemia, hyperinsulinemia, insulin resistance, hypertension, body and epididymal fat gain, plasma lipids abnormalities and pain neuropathy in chronically glucose-fed rats [8,13–16]. This evidence concerns the gene BDKRB1 and hyperinsulinism.